相关实验视频
Updated: May 15, 2025

11:51
Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
11.8K
作为抗癌剂的纳夫托金盐的设计,合成和生物评估
Yao Cheng1, Tsz Tin Yu1, Ellen M Olzomer2
1School of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia.
Molecules (Basel, Switzerland)
|May 14, 2025
概括
研究人员开发了基于BH10的新盐化合物,以准癌症中的华堡效应. 化合物7b通过与Keap1相互作用,显示出显著的抗癌活性和选择性,提供了一个有前途的治疗策略.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 华堡效应是癌症的标志,涉及改变的葡萄糖分解,并呈现出治疗点.
- BH10是一种先前已识别的化合物,破坏癌细胞糖解,并表明Kelch-like ECH相关蛋白1 (Keap1) 是一个潜在的目标.
- 提高BH10的功效和选择性对于开发有效的抗癌药物至关重要.
研究的目的:
- 合成和评估新的BH10衍生盐化合物,以提高抗癌活性和选择性.
- 调查这些化合物与Keap的分子相互作用1.1.
主要方法:
- 从BH10.10获得的纳夫托伊米达盐类型库的合成.
- 在体外抗癌活性和选择性测定.
- 分子对接研究以阐明与Keap的结合相互作用1.1.
主要成果:
- 化合物7b表现出强大的纳米分子抗癌活性 (IC50 = 22.97 nM).
- 化合物7b具有很高的选择性,选择性比为41.43.
- 分子对接证实,纳夫托伊米达盐类型通过碳基介导相互作用和键结合与Keap1结合.
结论:
- 由BH10衍生而来的纳夫托伊米达盐类类似物代表了一类有前途的抗癌药物,其向的目标是华堡效应.
- 化合物7b是一种高度强效和选择性抑制剂,具有进一步治疗开发的潜力.
- 用这些新型化合物准Keap1为选择性癌症治疗提供了一个可行的策略.
相关概念视频
Structure-Activity Relationships and Drug Design
460
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
460
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
141
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
141
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
152
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
152

